

Table of Contents

Volume 1

PART I. INTRODUCTION

CHAPTER 1. INTRODUCTION TO THE PUBLICLY TRADED CORPORATION

I. INTRODUCTION

- § 1:1 Scope of treatise
- § 1:2 Identifying the publicly traded corporation
- § 1:3 —Definition
- § 1:4 —Distinction between publicly traded corporation and closely held corporation

II. SOURCES OF LAW

- § 1:5 State corporation and securities statutes
- § 1:6 Federal regulation
- § 1:7 —Securities Act of 1933
- § 1:8 —Securities Exchange Act of 1934
- § 1:9 —Securities and Exchange Commission
- § 1:10 —Securities exchanges
- § 1:11 Sources of corporate governance regulation

CHAPTER 2. CORPORATE GOVERNANCE

I. GENERAL CONTROL STRUCTURE

- § 2:1 General control structure—Introduction
- § 2:2 —Separation of ownership and control—Antecedents to modern corporate governance
- § 2:3 — —Berle and Means: *The Modern Corporation and Private Property*
- § 2:4 —Objectives of laws governing publicly traded corporations
- § 2:5 —“Shareholder primacy” model of corporate governance
- § 2:6 —Shareholder primacy and “long-term shareholders”
- § 2:7 —Alternatives to shareholder primacy: Board primacy; Director primacy

- § 2:8 —Alternatives to shareholder primacy: Stakeholder model; Stakeholderism; “Team production” and maximizing stakeholder value

II. SHAREHOLDERS’ ROLES

- § 2:9 Role of shareholders in management of publicly traded corporation
- § 2:10 —Shareholder activism of institutional investors and hedge funds
- § 2:11 —Program and high-frequency trading

III. DIRECTORS’ ROLES

- § 2:12 The board primacy model—The prevailing model of the corporation
- § 2:13 —Introduction
- § 2:14 —Overview of theories
- § 2:15 —The “wise ruler” theorists
- § 2:16 —The “long-term interests” theorists
- § 2:17 *[Reserved]*
- § 2:18 Role of directors
- § 2:19 Duties of directors and board
- § 2:20 —Duty of care and business judgment rule
- § 2:21 —Duty of loyalty
- § 2:22 Role of independent directors
- § 2:23 —Myth and reality—Investigations into the Enron implosion
- § 2:24 — —Perceived or potential shortcomings of independent directors
- § 2:25 Role of inside directors
- § 2:26 Role of committees—Overview
- § 2:27 —Audit committees
- § 2:28 —Nominating/corporate governance committees
- § 2:29 —Compensation committees
- § 2:30 —Definition of “independent”
- § 2:31 —Other committees
- § 2:32 Interlocking boards

IV. OFFICERS’ ROLES

- § 2:33 Role of officers in publicly traded corporation

V. ROLE OF MARKET IN CONTROL OF PUBLICLY TRADED CORPORATION

- § 2:34 Market as control

TABLE OF CONTENTS

§ 2:35 Trends in corporate governance

**VI. EXAMPLES OF CORPORATE GOVERNANCE
POLICIES AND PRINCIPLES**

- § 2:36 CalPERS—CalPERS’s Governance & Sustainability Principles
- § 2:37 —CalPERS Investment Beliefs
- § 2:38 —Proxy Voting Guidelines
- § 2:39 TIAA-CREF Policy Statement on Corporate Governance—6th Edition
- § 2:40 Council of Institutional Investors—Generally
- § 2:41 —Definition of an independent director
- § 2:42 Statement of the Council of Institutional Investors—Protecting Fundamental Shareholder Rights
- § 2:43 The Council of Institutional Investors’ corporate governance policies
- § 2:44 Business Roundtable: Principles of Corporate Governance
- § 2:45 Institutional Shareholder Services (ISS) White papers
- § 2:46 The Conference Board—Corporate Board Practices in the Russell 3000 and S&P 500
- § 2:47 Corporate governance resource links—Business Roundtable Links
- § 2:48 [*Reserved*]
- § 2:49 Corporate governance resource links—Other useful links
- § 2:50 —ALI’s Restatement of the Law of Corporate Governance

**CHAPTER 3. DELAWARE CORPORATE
LAW—STANDARDS OF CONDUCT AND
STANDARDS OF REVIEW**

- § 3:1 Introduction—Overview of Delaware’s standards of conduct/review
- § 3:2 Shareholder actions—Standing to sue
- § 3:3 —Direct v. derivative suits
- § 3:4 Demand futility in shareholder derivative litigation—Overview
- § 3:5 —Historical background—*Aronson*, *Rales*, and the Universal 3-part test
- § 3:6 —Universal 3-part test for demand futility—Overview
- § 3:7 — —First prong of the Universal Test
- § 3:8 — —Second prong of the Universal Test
- § 3:9 — —Third prong of the Universal Test

- § 3:10 The business judgment rule—Overview
- § 3:11 —Exceptions
- § 3:12 —Presumptions/rebutting presumptions
- § 3:13 —American Law Institute’s formulation
- § 3:14 Fiduciary duties—Generally
- § 3:15 —Overview
- § 3:16 —The duty of care and the duty to be informed
- § 3:17 —Duty of loyalty—Overview
- § 3:18 —Duty of loyalty and the absence of conflicting interests
- § 3:19 —Good faith/bad faith—Overview
- § 3:20 — —Three categories of bad faith
- § 3:21 Fiduciary duties amid options backdating
- § 3:22 Enhanced scrutiny—The *Unocal* test—Overview
- § 3:23 — —Reasonable grounds for believing there is a danger to corporate policy and effectiveness
- § 3:24 — —The reasonableness of the defensive response in relation to the threat posed
- § 3:25 —*Revlon*—Overview
- § 3:26 — —What circumstances trigger the duty to seek the best value?
- § 3:27 — —How to seek the best value
- § 3:28 — —When does the duty to seek the best value not apply?
- § 3:29 —*Blasius*
- § 3:30 The entire fairness test—Introduction and overview
- § 3:31 —Controlling shareholders
- § 3:32 —*MFW* cleansing
- § 3:33 —Burden shifting analysis
- § 3:34 —Mergers with unaffiliated third-parties
- § 3:35 —Entrenchment motive and the inapplicability of entire fairness to decisions not to sell the company
- § 3:36 —Exculpated claims
- § 3:37 Subversion of corporate democracy—The *Schnell / Blasius* review
- § 3:38 Stockholder ratification defense—Director self-compensation decisions
- § 3:39 Special litigation committees—*Zapata Corp. v. Maldonado*

PART II. FEDERAL SECURITIES LAWS

CHAPTER 4. FEDERAL SECURITIES LAW— DEFINITION OF “SECURITY”

- § 4:1 Definition of security—Overview
- § 4:2 —The statutory definition of a “security”
- § 4:3 Investment contracts as securities—Overview: *SEC v. W.J. Howey Co.*
- § 4:4 —Test for investment contracts under *S.E.C. v. Howey*
- § 4:5 —Investment of money
- § 4:6 —Common enterprise
- § 4:7 —Expectation of profit
- § 4:8 —Profits derived “solely” from the efforts of others
- §§ 4:9 to 4:19 [*Reserved*]
- § 4:20 General partnership interests as securities—
Williamson v. Tucker—Overview
- § 4:21 — —The first *Williamson* factor
- § 4:22 — —The second *Williamson* factor
- § 4:23 — —The third *Williamson* factor
- § 4:24 LLC interests as securities—Overview
- § 4:25 —First Circuit [*Reserved*]
- § 4:26 —Second Circuit
- § 4:27 —Third Circuit
- § 4:28 —Fourth Circuit
- § 4:29 —Fifth Circuit
- § 4:30 —Sixth Circuit
- § 4:31 —Seventh Circuit
- § 4:32 —Eighth Circuit
- § 4:33 —Ninth Circuit
- § 4:34 —Tenth Circuit—Six-factor “ability-to-control” test
- § 4:35 —Eleventh Circuit
- §§ 4:36 to 4:39 [*Reserved*]
- § 4:40 Notes as securities and the *Reves* test—Overview
- § 4:41 —Factor 1: motivation
- § 4:42 —Factor 2: plan of distribution
- § 4:43 —Factor 3: public perception
- § 4:44 —Factor 4: Risk-reducing factors
- § 4:45 —Example—*Stoiber v. SEC*
- §§ 4:46 to 4:49 [*Reserved*]
- § 4:50 Other potential securities—Pyramid schemes; Ponzi
schemes as securities
- § 4:51 —Distributorships; Sale-leasebacks; Leases

- § 4:52 —Managed commodity trading accounts
- § 4:53 —Viatical settlements; Life settlements; Variable annuities
- § 4:54 —Pension plans
- § 4:55 —Real estate schemes and investments
- § 4:56 —Bank instruments; Certificates of deposit
- § 4:57 —Cryptocurrencies and digital tokens as securities
- § 4:58 —Miscellaneous

CHAPTER 5. SECURITIES ACT OF 1933— REGISTRATION

- § 5:1 Introduction & reform efforts—Overview
- § 5:2 —SEC enforcement
- § 5:3 —2005 Securities offering reform—Overview
- § 5:4 — —Five tiers of issuers
- § 5:5 — —“On-demand” SEC-registration for well-known seasoned issuers
- § 5:6 — —Additional reforms
- § 5:7 —2012 JOBS Act—Overview
- § 5:8 — —Emerging growth companies
- § 5:9 — —Allowing general solicitations under Regulation D and Rule 144A
- § 5:10 — —Brief summary of other initiatives
- § 5:11 —FAST Act Modernization and Simplification
- §§ 5:12 to 5:19 *[Reserved]*
- § 5:20 Structure of the 1933 Act
- § 5:21 Definitions under the 1933 Act—“Sale” / “sell” / “offer” / “offer to sell” / “offer to buy”
- § 5:22 —Issuer
- § 5:23 —Underwriter—Introduction
- § 5:24 — —Purchasing securities with a “view towards distribution”
- § 5:25 — —Participating in an underwriting
- § 5:26 — —Participating in a distribution
- § 5:27 — —Control prong
- § 5:28 — —Presumptions; Negating presumptions; Inadvertent underwriters
- § 5:29 —Dealer
- § 5:30 —Prospectus
- § 5:31 —Accredited investor
- § 5:32 —Emerging growth company
- §§ 5:33 to 5:39 *[Reserved]*
- § 5:40 Registration under the 1933 Act—Section 5—Overview
- § 5:41 — —Section 5 involves three time periods

TABLE OF CONTENTS

- § 5:42 — —Policies underlying Section 5
- § 5:43 — —Elements of a Section 5 violation—SEC enforcement
- § 5:44 — — —Comparing private actions under Section 12(a)(1)
- § 5:45 — —Exemptions and safe harbors
- §§ 5:46 to 5:59 [*Reserved*]
- § 5:60 Registration under the 1933 Act—The IPO process—Introduction and overview
- § 5:61 — —Pre-IPO financing
- § 5:62 — —Pros and cons of going public
- § 5:63 — —Traditional IPO process
- § 5:64 —The underwriting process
- § 5:65 —Registration statements and prospectuses
- § 5:66 — —Detailed requirements
- § 5:67 —Three time periods
- § 5:68 —The pre-filing period
- § 5:69 — —Offers to sell
- § 5:70 —The waiting period
- § 5:71 — —Permissible offers
- § 5:72 —The post-effective period
- § 5:73 —SEC efforts to expand permitted general solicitations; Testing-the-waters
- § 5:74 Integrated disclosure
- § 5:75 Scaled disclosure for smaller reporting companies
- § 5:76 Emerging Growth Companies—IPO on-ramp
- § 5:77 Alternatives to traditional IPOs—Direct listings
- § 5:78 —Special Purpose Acquisition Companies (SPACs)
- § 5:79 —Initial coin offerings (“ICOs”)

CHAPTER 5A. SECURITIES ACT OF 1933—EXEMPTIONS

- § 5A:1 Introduction
- § 5A:2 Exemptions under Section 3
- § 5A:3 Section 3(a)(2) exemption—Certain Government/municipality offerings—Overview
- § 5A:4 — —Future deliveries; Options; Repurchase agreements
- § 5A:5 — —Municipal securities; Industrial development bonds.
- § 5A:6 — —Application of antifraud provisions
- § 5A:7 Section 3(a)(2) and Section 3(a)(5) exemptions—Certain bank offerings; Certain savings and loan offerings—Overview
- § 5A:8 — —3(a)(5) exemption for savings and loan offerings

PUBLICLY TRADED CORPORATIONS

- § 5A:9 — —Certificates of deposit
- §§ 5A:10 to 5A:19 *[Reserved]*
- § 5A:20 Section 3(a)(3) exemption—Short-term commercial paper
- § 5A:21 Section 3(a)(4) exemption—Certain educational, charitable, or nonprofit offerings
- § 5A:22 Section 3(a)(6) exemption—Certain railroad trusts
- § 5A:23 Section 3(a)(7) exemption—Certain certificates issued by receivers/trustees in Chapter 11 Bankruptcy
- § 5A:24 Section 3(a)(8) exemption—Certain insurance policies/annuity contracts
- § 5A:25 Section 3(a)(9) exemption—Securities exchanged with existing shareholders
- § 5A:26 Section 3(a)(10) exemption—Securities issued in approved reorganizations
- §§ 5A:27 to 5A:39 *[Reserved]*
- § 5A:40 Section 3(a)(11) exemption—Intrastate offerings and Rule 147/Rule 147A—Section 3(a)(11)
- § 5A:41 — —Rule 147: Intrastate offers and sales
- § 5A:42 — —Rule 147A: Intrastate sales exemption
- § 5A:43 Section 3(a)(12) exemption—Certain issuances in connection with bank holding companies/savings and loan associations
- § 5A:44 Section 3(a)(13) exemption—Certain church pension plans
- § 5A:45 Section 3(a)(14) exemption—Certain security futures products
- §§ 5A:46 to 5A:49 *[Reserved]*
- § 5A:50 Section 3(b)(1) & (2)—Small issues exemptive authority
- § 5A:51 Private placements—Section 4(a)(2) exemption
- § 5A:52 Accredited investor exemption—Section 4(a)(5)
- §§ 5A:53 to 5A:59 *[Reserved]*
- § 5A:60 Regulation crowdfunding—Overview of the crowdfunding exemption
- § 5A:61 —Disclosure requirements
- § 5A:62 —Reporting, filing, advertising, and solicitations of interest
- § 5A:63 —Intermediaries
- § 5A:64 —Funding portals
- § 5A:65 —Miscellaneous provisions
- §§ 5A:66 to 5A:69 *[Reserved]*
- § 5A:70 Regulation A—Background and Overview
- § 5A:71 —Scope of exemption

TABLE OF CONTENTS

§ 5A:72	—Offering statement; Filing and notification requirements
§ 5A:73	—Solicitation of interest (testing the waters)
§ 5A:74	—Ongoing reporting
§ 5A:75	—Other considerations
§§ 5A:76 to 5A:79	<i>[Reserved]</i>
§ 5A:80	Regulation D—Introduction
§ 5A:81	—Rule 501—“Accredited investor” and other definitions
§ 5A:82	—Rule 502(b); Rule 502(c); Rule 502(d)
§ 5A:83	—Rule 503—Electronic filing and notice requirements
§ 5A:84	—Rule 504: Exemption for limited offerings and sales of securities not exceeding \$10 million
§ 5A:85	—Rule 506—Exemption for limited offers and sales without regard to dollar amount of offering
§ 5A:86	—Rule 507: Disqualifying provisions
§ 5A:87	—Rule 508: Insignificant deviations from a term, condition or requirement of Regulation D
§§ 5A:88 to 5A:89	<i>[Reserved]</i>
§ 5A:90	Rule 701—Compensatory benefit plans and contracts—Introduction and overview.
§ 5A:91	— —Availability/eligibility
§ 5A:92	— —Transactions under Rule 701.
§ 5A:93	— —Mandatory disclosures.
§ 5A:94	— —Restricted securities; Resale limitations
§ 5A:95	— —Miscellaneous
§§ 5A:96 to 5A:99	<i>[Reserved]</i>
§ 5A:100	The Section 4(a)(1) exemption for transactions by nonprofessionals
§ 5A:101	Secondary transactions—SEC Rule 144—Introduction and overview
§ 5A:102	— —Certain definitions
§ 5A:103	— —Application of Rule 144
§ 5A:104	Rule 144A exemption for private placements with institutional investors
§ 5A:105	Section 4(a)(7) exemption for sales to accredited investors and the Section 4(a)(1½) exemption for secondary private placements—Section 4(a)(1½) exemption for secondary private placements
§ 5A:106	—Section 4(a)(7) exemption
§ 5A:107	Section 4(a)(3) exemption—The dealers’ exemption.
§ 5A:108	Integration of offerings—SEC Rule 152 and the new integration doctrine

Volume 2

CHAPTER 5B. SECURITIES ACT OF 1933— LIABILITY & REMEDIES

- § 5B:1 Private remedies under the 1933 Act—Overview
- § 5B:2 Section 11—Introduction
- § 5B:3 —Pleading Section 11 claims—Generally
- § 5B:4 —Claims that “Sound in fraud”
- §§ 5B:5 to 5B:9 *[Reserved]*
- § 5B:10 Section 11—Elements of a Section 11 claim—
Generally
- § 5B:11 —Elements—Purchasing securities from issuer;
Tracing aftermarket purchases—Generally
- § 5B:12 — — —Second Circuit
- § 5B:13 — — —Third Circuit
- § 5B:14 — — —Ninth Circuit
- § 5B:15 — — —Eleventh Circuit
- § 5B:16 — —Defendant participated in the offering in a
manner sufficient to give rise to liability under
section 11—Generally
- § 5B:17 — —Material misstatement/omission—
Misstatement/omission—Generally
- § 5B:18 — — —Misrepresentation and falsity
- § 5B:19 — — —Omissions
- § 5B:20 — — —Opinion/beliefs—Generally
- § 5B:21 — — — —*Omnicare*
- § 5B:22 — — —Materiality—Generally
- § 5B:23 — — —Fact-specific and contextual inquiry
- § 5B:24 — — —Item 303 of Regulation S-K
- § 5B:25 — — —Item 105 of Regulation S-K; Disclosing risk
factors
- § 5B:26 — — —Materiality and efficient markets
- § 5B:27 — — —Earnings and financial statements
- § 5B:28 — — —Bespeaks caution doctrine
- § 5B:29 — —No reliance requirement
- § 5B:30 — —No Scierter requirement
- § 5B:31 —Section 11(f)—Joint and several liability; Right to
contribution
- §§ 5B:32 to 5B:39 *[Reserved]*
- § 5B:40 Section 11—Defenses—Generally
- § 5B:41 — —Section 11(b)(1); Plaintiff’s knowledge of
untruth/omission (the “knowledge defense”)
- § 5B:42 — —Due diligence—Generally
- § 5B:43 — —Reasonable investigation standard—
Generally

TABLE OF CONTENTS

§ 5B:44	— — — —Inside directors; Executive management
§ 5B:45	— — — —Outside directors
§ 5B:46	— — — —Underwriters
§ 5B:47	— — — —Accountants
§ 5B:48	— — — —Comparing Section 12(a)(2)'s defense of reasonable care
§ 5B:49	— — —Section 11(a)(4)
§ 5B:50	— —Reliance defense under Section 11(b)(3)(C)
§ 5B:51	— —Section 11(e); Negative causation.
§ 5B:52	—Damages
§ 5B:53	—Statute of limitations
§§ 5B:54 to 5B:59	<i>[Reserved]</i>
§ 5B:60	Section 12(a)(1)
§ 5B:61	Comparing Section 12(a)(1) with Section 12(a)(2)
§ 5B:62	Section 12(a)(2)—Overview
§ 5B:63	—Elements of a claim
§ 5B:64	—Elements—The defendant is a “statutory seller”
§ 5B:65	—Date of “sale”
§ 5B:66	—Elements—No scienter or reliance requirements
§ 5B:67	—Remedies and damages
§ 5B:68	Section 12—Defenses—Statute of limitations
§ 5B:69	Section 12(a)(2)—Defenses—Plaintiff’s knowledge of the untruth or omission
§ 5B:70	— —Loss causation as an affirmative defense
§ 5B:71	— —Reasonable care defense
§ 5B:72	Control-person liability
§ 5B:73	Section 17—Overview

CHAPTER 6. SECURITIES EXCHANGE ACT OF 1934—REGISTRATION, REPORTING, AND DISCLOSURE

§ 6:1	Securities Exchange Act of 1934—Introduction
§ 6:2	Registration Requirements—Who must register under the 1934 Exchange Act
§ 6:3	—Suspension of trading; Cessation of trading; Deregistration
§ 6:4	—Procedure for registration; Information
§ 6:5	—Exemption from registration requirements
§§ 6:6 to 6:9	<i>[Reserved]</i>
§ 6:10	Reporting Requirements—Periodic and continuous disclosure and reporting
§ 6:11	—Reporting under proxy regulations
§ 6:12	—Reporting under tender offer regulations
§ 6:13	Reporting requirements—Reporting under Sections 13(d) and 16(a)

PUBLICLY TRADED CORPORATIONS

- § 6:14 Reporting Requirements—Reporting requirement under Section 15(d)
- § 6:15 —Voluntary reporting
- §§ 6:16 to 6:19 *[Reserved]*
- § 6:20 Periodic disclosure requirements—Annual reports—Overview
- § 6:21 —Sarbanes-Oxley Act modifications
- § 6:22 —Quarterly reports—Overview
- § 6:23 —Sarbanes-Oxley Act modifications
- § 6:24 —Interim Reports—Overview
- § 6:25 — —Sarbanes-Oxley and post-Sarbanes-Oxley modifications
- §§ 6:26 to 6:29 *[Reserved]*
- § 6:30 Disclosure requirements under Regulation S-K—Item 10—Generally
- § 6:31 — —SEC’s interpretive responses
- § 6:32 —Item 101
- § 6:33 —Item 102—Description of principal properties
- § 6:34 —Item 103—Pending legal proceedings—Generally
- § 6:35 — — —SEC’s interpretive responses
- § 6:36 —Item 105—Risk factors
- § 6:37 —Item 201—Market price of common equity; Dividends on common equity; Related stockholder matters—Generally
- § 6:38 — — —SEC’s interpretive responses
- § 6:39 —Item 202—Description of Securities
- § 6:40 —Former Item 301—(Formerly concerned selected financial data)
- § 6:41 —Item 302—Supplementary financial information
- § 6:42 —Item 303—Management’s discussion and analysis (MD&A)—Generally
- § 6:43 — — —Judicial interpretations & analysis
- § 6:44 — — —Historical background
- § 6:45 —Item 304—Changes in and disagreements with accountants on accounting and financial disclosure—Generally
- § 6:46 — — —SEC’s interpretive responses
- § 6:47 —Item 305—Quantitative and qualitative disclosures about market risk
- § 6:48 —Item 307; Item 308—Internal controls—Generally
- § 6:49 — — —SEC’s interpretive responses
- § 6:50 —Item 401—Directors, executive officers, promoters and control persons—Generally
- § 6:51 — — —SEC interpretations and FAQs
- § 6:52 —Item 402—Executive compensation—Overview; Compensation discussion and analysis

TABLE OF CONTENTS

§ 6:53	— — —Certain specific disclosures
§ 6:54	— — —Disclosure of hedging by officers and directors
§ 6:55	— — —Shareholder Approval of Executive Compensation & Golden Parachute Compensation
§ 6:56	— — —“Say on pay”
§ 6:57	— — —Historical background
§ 6:58	— — —SEC’s interpretive responses
§ 6:59	—Item 403—Ownership of securities
§ 6:60	— — —SEC’s interpretive responses
§ 6:61	—Item 404—Transactions with related persons
§ 6:62	— — —SEC’s interpretive responses
§ 6:63	—Item 405 & Item 408—Disclosure of insider share transactions; Disclosure of insider trading arrangements and policies
§ 6:64	—Item 406—Disclosure of codes of ethics
§ 6:65	—Item 407—Disclosure of corporate governance matters—Generally
§ 6:66	— — —Historical background
§ 6:67	— — —SEC’s interpretive responses
§ 6:68	—Item 501—Cover page
§ 6:69	— — —SEC’s interpretive responses
§ 6:70	—Item 502—Table of contents
§ 6:71	—Item 503—Prospectus summary
§ 6:72	—Item 504—Use of proceeds
§ 6:73	—Item 505—Determination of offering price
§ 6:74	—Item 506—Dilution
§ 6:75	—Item 507—Selling security holders—Generally
§ 6:76	— — —SEC’s interpretive responses
§ 6:77	—Item 508—Plan of distribution
§ 6:78	—Item 509—Interests of named experts
§ 6:79	—Item 510—Disclosing SEC’s position on indemnification
§ 6:80	—Item 511—Disclosing expenses of issuance and distribution
§ 6:81	—Item 512—Disclosing certain undertakings— Generally
§ 6:82	— — —SEC’s interpretive responses
§ 6:83	—Item 601—Exhibits—Generally
§ 6:84	— — —SEC’s interpretive responses
§ 6:85	—Item 701—Sales of unregistered securities
§ 6:86	—Item 702—Disclosure of indemnification of directors and officers
§ 6:87	—Item 801—Securities Act industry guides
§ 6:88	—Item 802—Exchange Act Industry Guides
§ 6:89	—Other Items

- § 6:90 —Climate-related disclosures; ESG-related disclosures
- § 6:91 Delivery of disclosures—Electronic delivery
- §§ 6:92 to 6:99 *[Reserved]*
- § 6:100 Accounting obligations—Financial and accounting data
- § 6:101 — —GAAP
- § 6:102 — —Impact of Sarbanes-Oxley Act (“SOX”)
- § 6:103 — —Non-GAAP
- § 6:104 — —Section 13(b)(2)
- § 6:105 — —Audit requirements
- § 6:106 — —Auditor independence
- § 6:107 — —Materiality and SAB No. 99
- § 6:108 — —Liability of auditors and accountants
- § 6:109 Corporate governance and the 1934 Act—Generally
- § 6:110 Enforcement of registration and reporting requirements; Enforcement of SOX certifications
- § 6:111 SEC’s Plain English Rule—Overview
- § 6:112 —Rules on how to prepare prospectuses
- Appendix 6A. Plain English Disclosure—Updated SEC Staff Legal Bulletin
- Appendix 6B. Section 302 Certification of Principal Executive Officer and Principal Financial Officer
- Appendix 6C. Statement Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

CHAPTER 7. PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

I. INTRODUCTION, OVERVIEW AND BACKGROUND

- § 7:1 Introduction
- § 7:2 Background of PSLRA

II. SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

- § 7:3 Background of safe harbor for forward-looking statements
- § 7:4 Overview of safe harbor for forward-looking statements
- § 7:5 PSLRA’s two-prong analysis for forward-looking statements
- § 7:6 —First prong
- § 7:7 —Second prong

TABLE OF CONTENTS

- § 7:8 —Analysis
- § 7:9 PSLRA’s framework for forward-looking statements
- § 7:10 —Mere “puffery” and/or optimistic statements
- § 7:11 —Exclusions from safe harbor
- § 7:12 —No duty to update forward-looking statements
- §§ 7:13 to 7:17 [*Reserved*]

III. PROCEDURAL REFORMS

- § 7:18 Lead plaintiffs—Introduction and overview
- § 7:19 —The PSLRA’s framework for selecting presumptive lead plaintiffs
- § 7:20 —Multiple lead plaintiffs; Lead plaintiff comprising a “group of persons”
- § 7:21 —Rebutting the presumption; Disqualifying presumptive lead plaintiffs
- § 7:22 —Selection of counsel
- § 7:23 PSLRA—Modified loser pays; Restrictions on payment of attorneys’ fees
- § 7:24 —Stay on discovery
- § 7:25 Circuit-by-circuit analysis of the PSLRA’s scienter pleading standard
- § 7:26 Proportionate liability
- § 7:27 Dismissal with prejudice versus leave to amend complaint
- § 7:28 Changes to role of auditors
- § 7:29 Aiding and abetting

IV. PSLRA’S RICO BAR

- § 7:30 PSLRA’s RICO bar—Overview
- § 7:31 —Scope and application
- § 7:32 —Limitations on the PSLRA’s RICO bar
- § 7:33 —“Criminal conviction exception”
- § 7:34 —Miscellaneous
- § 7:35 —Retroactivity of RICO provisions

V. DAMAGES CAP

- § 7:36 Damages cap
- § 7:37 Retroactivity of the PSLRA

VI. UNIFORM STANDARDS ACT

- § 7:38 SLUSA—Overview
- § 7:39 SLUSA’s preclusion and removal provisions—Overview
- § 7:40 —SLUSA’s five-part test

- § 7:41 — —Covered class actions / covered securities
- § 7:42 — —Misrepresentation or omission
- § 7:43 — —The defendant must have misrepresented or omitted a material fact or employed a manipulative device or contrivance “in connection with the purchase or sale” of that security
- § 7:44 Delaware carve-outs exception to SLUSA’s preclusion provisions
- § 7:45 SLUSA—Complete dismissal vs. partial dismissal (*In re Lord Abbett*)

Appendix 7A. Joint Explanatory Statement of the Committee of Conference—Private Securities Litigation Reform Act of 1995

CHAPTER 8. SARBANES-OXLEY (2002); DODD-FRANK (2010); AND JOBS ACT (2012)

- § 8:1 Overview to the Sarbanes-Oxley Act of 2002
- § 8:2 Public company accounting oversight board
- § 8:3 Inspections, investigations, and disciplinary proceedings
- § 8:4 Accounting standards
- § 8:5 Limitations on non-audit services; preapproval requirement
- § 8:6 Audit partner rotation; conflicts of interest
- § 8:7 Auditor reports to audit committees
- § 8:8 Analyst conflicts of interest
- § 8:9 Public company audit committees
- § 8:10 Corporate responsibility for financial reports
- § 8:11 SOX 304—Forfeiture of bonuses and profits
- § 8:12 Prohibition of insider trading during pension fund blackout periods
- § 8:13 Loans to directors and executive officers prohibited
- § 8:14 Fair funds for investors
- § 8:15 Rules of professional responsibility for attorneys
- § 8:16 Financial disclosures in periodic reports
- § 8:17 Disclosures of transactions involving management and principal stockholders
- § 8:18 Management assessment of internal controls
- § 8:19 Code of ethics for senior financial officers
- § 8:20 Corporate and Criminal Fraud Accountability Act of 2002
- §§ 8:21 to 8:39 [*Reserved*]
- § 8:40 SOX whistleblower provisions—Overview of SOX 806 (18 U.S.C.A. § 1514A)
- § 8:41 —Administrative procedure

TABLE OF CONTENTS

§ 8:42	—Elements of a SOX whistleblower claim—Overview
§ 8:43	— —Protected activity
§ 8:44	— — —Reasonable belief
§ 8:45	— —Knowledge of decision-maker and unfavorable personnel action
§ 8:46	— —Employee suffered an adverse employment action
§ 8:47	— —Protected activity was a “contributing factor” to adverse employment action
§ 8:48	—Rebutting the prima facie case—Termination regardless of protected activity
§ 8:49	—Other—Whistleblower must be an employee or contractor of the defined public company
§ 8:50	—Statute of limitations
§ 8:51	—Rights and remedies
§§ 8:52 to 8:69	<i>[Reserved]</i>
§ 8:70	Dodd-Frank whistleblower provisions
§ 8:71	The SEC’s 2011 whistleblower provisions (as amended in 2020)— <i>Digital Realty v. Somers</i>
§ 8:72	—Examination of the 2011 SEC whistleblower rules
§ 8:73	—Elements of a Dodd-Frank retaliation claim
§ 8:74	SOX/Dodd-Frank whistleblower provisions—Retroactive application
§§ 8:75 to 8:89	<i>[Reserved]</i>
§ 8:90	White-collar crime penalty enhancements
§ 8:91	Corporate fraud accountability
§ 8:92	Dodd-Frank Act—Corporate governance provisions
§ 8:93	—Shareholder approval of executive compensation (“say on pay”)—Overview
§ 8:94	— —Separate resolution required
§ 8:95	— —Shareholder approval of golden parachute compensation
§ 8:96	— —2011 SEC Rules: <i>Shareholder Approval of Executive Compensation and Golden Parachute Compensation</i>
§ 8:97	— —Emerging growth companies (EGCs)
§ 8:98	—Compensation committees
§ 8:99	—Executive compensation disclosures
§ 8:100	—Recovery (clawback) of erroneously awarded compensation policy
§ 8:101	—Disclosure of hedging by employees and directors
§ 8:102	—Enhanced compensation structure reporting
§ 8:103	—Proxy access
§ 8:104	—Disclosures regarding chairman and CEO structures / corporate governance

- §§ 8:105 to 8:119 *[Reserved]*
 - § 8:120 “Jumpstart Our Business Startups Act” (“JOBS Act”) of 2012—Introduction and overview
 - § 8:121 —Structure of JOBS Act
 - § 8:122 The “Jumpstart Our Business Startups Act” (“JOBS Act”) of 2012—Emerging growth companies
 - § 8:123 “Jumpstart Our Business Startups Act” (“JOBS Act”) of 2012—Crowdfunding
- Appendix 8A. Auditing internal control over financial reporting

PART III. REGULATION OF COMMUNICATIONS TO SHAREHOLDERS UNDER THE 1934 EXCHANGE ACT

CHAPTER 9. PRIMER ON PROXY REGULATION

- § 9:1 Overview of federal proxy regulation
- § 9:2 —Definitions
- § 9:3 —Routine solicitation
- § 9:4 —Exempt solicitation
- § 9:5 —Proxy statements
- § 9:6 Exchange Act disclosure requirements for contested elections
- § 9:7 Disclosure required in annual report
- § 9:8 Obtaining shareholder lists
- § 9:9 Universal Proxy
- § 9:10 *[Reserved]*
- § 9:11 Section 14(a); Rule 14a-9—Overview
- § 9:12 —Culpability; state of mind
- § 9:13 —Pleading
- § 9:14 —Misleading statement or omission
- § 9:15 —Materiality
- § 9:16 —Causation; loss causation
- § 9:17 —Standing, injury, and relief
- § 9:18 —Statute of limitations
- § 9:19 Internet availability of proxy materials
- § 9:20 —Additional provisions of the electronic notice and access model
- § 9:21 Shareholder choice regarding proxy materials
- § 9:22 —Differences between the “full set delivery option” and the “notice only option”

TABLE OF CONTENTS

- § 9:23 —The “full set delivery option”: Sending a notice with a full set of proxy materials
 - § 9:24 Electronic shareholder forums
 - § 9:25 Electronic Shareholder Forums and Rule 14a-2(b)(6) exemption
 - § 9:26 Rule 14a-17
 - § 9:27 The SEC’s 2009 Proxy Disclosure Enhancements
 - § 9:28 Facilitating shareholder director nominations
 - § 9:29 Exemptions from the Proxy Rules for Proxy Voting Advice
 - § 9:30 Reporting of Executive Compensation Votes by Institutional Investment Managers
- Appendix 9A. Proxy Rules—Compliance and Disclosure Interpretations

Volume 3

CHAPTER 10. SHAREHOLDER PROPOSALS

- § 10:1 Overview
- § 10:2 Definition of “shareholder proposal”
- § 10:3 Logistics of shareholder proposals—Eligibility
- § 10:4 —Limitations on submissions
- § 10:5 —Deadlines
- § 10:6 Procedural grounds for excluding shareholder proposal
- § 10:7 Attendance at shareholder meeting
- § 10:8 Exclusion of shareholder proposal
- § 10:9 Procedures for exclusions
- § 10:10 Shareholder’s response
- § 10:11 Accompanying information
- § 10:12 Exclusions under Rule 14a-8(i)(1)—Improper under state law
- § 10:13 Exclusions under Rule 14a-8(i)(2)—Violation of law
- § 10:14 Exclusions based on Rule 14a-8(i)(3)—Violation of proxy rules
- § 10:15 Exclusions based on Rule 14a-8(i)(4)—Personal grievance; special interest
- § 10:16 Exclusions based on Rule 14a-8(i)(5)—Relevance
- § 10:17 Exclusions based on Rule 14a-8(i)(6)—Absence of power/authority
- § 10:18 Exclusions based on Rule 14a-8(i)(7)—Management functions
- § 10:19 Exclusions based on Rule 14a-8(i)(8)—Relates to election

- § 10:20 Commission interpretation of Rule 14a-8(i)(8)
- § 10:21 2007 amendment to Rule 14a-8(i)(8) and subsequent SEC guidance
- § 10:22 Exclusions based on Rule 14a-8(i)(9)—Conflicts with company’s proposal
- § 10:23 Exclusions based on Rule 14a-8(i)(10)—Substantially implemented
- § 10:24 Exclusions based on Rule 14a-8(i)(11)—Duplication
- § 10:25 Exclusions based on Rule 14a-8(i)(12)—Resubmissions
- § 10:26 Exclusions based on Rule 14a-8(i)(13)—Specific amount of dividends

PART IV. CORPORATE MISREPRESENTATION AND DISCLOSURE

CHAPTER 11. SECURITIES FRAUD UNDER RULE 10B-5—ELEMENTS; STANDING; “IN CONNECTION WITH”; “SCHEME LIABILITY”; AND “MAKER LIABILITY”

- § 11:1 Elements of a claim under Rule 10b-5
- § 11:2 Standing—Constitutional standing—Generally
- § 11:3 — —Establishing injury in fact
- § 11:4 — —Traceability
- § 11:5 — —Other
- § 11:6 —Purchaser/seller requirement
- § 11:7 —Standing and the “forced seller” doctrine
- § 11:8 Standing requirement vs. “in connection with” requirement
- §§ 11:9 to 11:29 *[Reserved]*
- § 11:30 The “in connection with” element—Generally
- § 11:31 —When a misrepresentation occurs “in connection with” the purchase/sale of a security
- § 11:32 —Satisfying the “in connection with” requirement
- § 11:33 —Scheme liability
- § 11:34 —Other
- § 11:35 The interplay between “in connection with,” causation, and reliance
- §§ 11:36 to 11:49 *[Reserved]*
- § 11:50 Market manipulation and scheme liability—Overview
- § 11:51 —Congressional and judicial policies underlying the prohibition of market manipulation

TABLE OF CONTENTS

- § 11:52 —Stating a market manipulation claim under Rule 10b-5(a) or (c)
- § 11:53 —Interplay between Rules 10b-5(a), (b), and (c)—*Lorenzo v. SEC*
- § 11:54 — —Second Circuit’s application of *Lorenzo* in *S.E.C. v. Rio Tinto*
- § 11:55 —Manipulative or deceptive acts—Falsity, deception, and non-disclosure
- § 11:56 — —Market activity; Market manipulation
- § 11:57 —Scheme liability—Generally
- § 11:58 — —*Lorenzo v. SEC*—Pre-*Lorenzo* case law
- § 11:59 — — —Generally
- § 11:60 — —Post-*Lorenzo* caselaw—“something extra” or “something more”
- § 11:61 — —Examples of inherently deceptive conduct
- § 11:62 — —Scienter
- § 11:63 — —Reliance and *Stoneridge*
- § 11:64 to 11:79 [*Reserved*]
- § 11:80 “Maker liability” claims—“Scheme liability” vs “Maker liability”
- § 11:81 —Identifying “makers” of statements—Impact of *Central Bank* and *Janus Capital Group*
- § 11:82 — —Defining the “maker” of a statement
- § 11:83 — —Corporate officials and those with “ultimate authority”; Other participants
- § 11:84 — —Effect of multiple legal entities on who has the final say; effect of intermediaries
- § 11:85 — —Auditors as “speechwriters”
- § 11:86 —Limiting holding of *Janus* to Rule 10b-5
- § 11:87 —Impact of *Janus* on the group pleading doctrine / group published doctrine
- § 11:88 —Clarifying the impact of *Janus*

CHAPTER 12. SECURITIES FRAUD UNDER RULE 10B-5—MATERIAL MISREPRESENTATION OR OMISSION; FALSITY; DUTY TO DISCLOSE

- § 12:1 Introduction and overview—Background
- § 12:2 —Standards of materiality
- § 12:3 —Materiality and policies underlying securities law
- § 12:4 —Immateriality as a matter of law
- § 12:5 Pleading materiality and falsity
- § 12:6 Materiality and class certification
- §§ 12:7 to 12:19 [*Reserved*]

PUBLICLY TRADED CORPORATIONS

- § 12:20 Materiality—Overview
- § 12:21 —*Matrixx Initiatives, Inc. v. Siracusano*
- § 12:22 —SEC Staff Accounting Bulletin No. 99
- § 12:23 —Item 303 of Regulation S-K
- § 12:24 —Risk disclosures; Disclosures under Item 105
(formerly Item 503(c)) of Regulation S-K
- § 12:25 —Materiality in the context of an efficient securities
market
- § 12:26 —Historical background of materiality in the Third
Circuit
- § 12:27 —Mergers/tender offers
- § 12:28 —Statements and omissions must be viewed in
context
- § 12:29 Materiality and the passage of time
- §§ 12:30 to 12:39 [*Reserved*]
- § 12:40 Falsity—Defining falsity; Falsity must be viewed in
context
- § 12:41 —Incomplete statements
- § 12:42 —Pleading falsity
- § 12:43 —Accurate statements; Technically accurate but
misleading statements; Projections; Forecasts
- § 12:44 —Falsity and violations of GAAP
- § 12:45 —Restatement of financials as evidence of falsity;
Misreported financial data
- § 12:46 —Statements must be “false when made”;
Contemporaneous falsity
- § 12:47 —Miscellaneous issues with falsity
- §§ 12:48 to 12:58 [*Reserved*]
- § 12:59 Misleading omissions
- § 12:60 Duty to disclose—Overview
- § 12:61 —No duty to disclose information in the public
domain or information that is common knowledge;
Truth on the market
- § 12:62 —Duty to disclose viewed as a continuum
- § 12:63 —When there is a fiduciary duty of disclosure; When
there is a special relationship between the parties
- § 12:64 —Triggering the duty to disclose with general vs.
specific statements
- § 12:65 —Duty to disclose fully
- § 12:66 —Duty to correct and duty to update
- § 12:67 —Specific fact patterns—Duty to disclose negative
test results
- § 12:68 — —Duty to disclose prior criminal record
- § 12:69 — —Duty to disclose criminal conduct
- § 12:70 — —Duty to disclose uncharged illegal activity;

TABLE OF CONTENTS

	Duty to disclose violations of law; Duty to disclose illicit or improper sources of revenue
§ 12:71	— —Duty to disclose corporate mismanagement
§ 12:72	— —Possible NASDAQ delisting
§§ 12:73 to 12:89	<i>[Reserved]</i>
§ 12:90	Fact vs. Opinion—Introduction
§ 12:91	— <i>Virginia Bankshares</i>
§ 12:92	— <i>Omnicare</i> —Introduction
§ 12:93	— —Statements of belief or opinion
§ 12:94	— <i>Tongue v. Sanofi</i>
§ 12:95	— <i>City of Dearborn Heights v. Align Tech.</i>
§ 12:96	—Predictions
§ 12:97	—Actionability of opinions in the Sixth Circuit
§ 12:98	Fact vs. opinion—Opinions about adequacy of loss reserves
§ 12:99	—SOX Certifications regarding internal controls
§§ 12:100 to 12:119	<i>[Reserved]</i>
§ 12:120	Safe harbors—Forward-looking statements
§ 12:121	— —Identifying statements as forward-looking
§ 12:122	— —Oral or written forward-looking statements
§ 12:123	— —Statements of assumptions as forward-looking
§ 12:124	— —Current statements predicated on projections of future events
§ 12:125	— —Actual knowledge for false and misleading forward-looking statements
§ 12:126	— —Distinguishing backward-looking statements concerning future events
§ 12:127	— —Examples of nonactionable forward-looking statements
§ 12:128	— —Mixed present/future statements
§ 12:129	— —Meaningful cautionary language—Overview
§ 12:130	— —Cautionary statements must “accompany” disclosures
§§ 12:131 to 12:139	<i>[Reserved]</i>
§ 12:140	Safe harbors—Other safe harbors—True or accurate disclosures
§ 12:141	— —Literally true and accurate statements
§ 12:142	— —Statements of opinion
§ 12:143	— —Puffery
§ 12:144	— — —Nonactionable puffery or vague, soft information
§ 12:145	— — —Puffery defense in the Fifth Circuit
§ 12:146	— — —Examples of nonactionable puffery

CHAPTER 13. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER

I. INTRODUCTION AND OVERVIEW

- § 13:1 Overview
- § 13:2 Pleading scienter with particularity under Rule 9(b)
- § 13:3 Pleading scienter with particularity under the PSLRA
- § 13:4 Pleading a strong inference of scienter under *Tellabs*
- § 13:5 *Tellabs* and the 50/50 equipoise scenario
- § 13:6 Purpose of heightened pleading standard
- § 13:7 Legislative intent behind the PSLRA

II. CIRCUIT-BY-CIRCUIT OVERVIEW OF SCIENTER/RECKLESSNESS STANDARD

- § 13:8 Introduction—Circuit-by-circuit analysis of scienter/
recklessness standard
- § 13:9 D.C. Circuit
- § 13:10 First Circuit
- § 13:11 Second Circuit
- § 13:12 Third Circuit
- § 13:13 Fourth Circuit
- § 13:14 Fifth Circuit
- § 13:15 Sixth Circuit
- § 13:16 Seventh Circuit
- § 13:17 Eighth Circuit
- § 13:18 Ninth Circuit
- § 13:19 Tenth Circuit
- § 13:20 Eleventh Circuit
- § 13:21 to 13:29 [*Reserved*]
- § 13:30 Liability of auditors and accountants

CHAPTER 13A. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER—FIRST CIRCUIT

- § 13A:1 Overview
- § 13A:2 General considerations
- § 13A:3 Motive and opportunity—Generally
- § 13A:4 —Inferring scienter (motive) from insider trading
- § 13A:5 — —Insider trading defenses—10b5-1 trading plans
- § 13A:6 Recklessness—Generally
- § 13A:7 Inferring scienter (recklessness) from GAAP
violations

TABLE OF CONTENTS

- § 13A:8 Inferring scienter (recklessness) from the restatement of financials
- § 13A:9 Inferring scienter (recklessness) from internal control deficiencies
- § 13A:10 Inferring scienter (recklessness) amid obvious danger of misleading investors
- § 13A:11 Inferring scienter (recklessness) when defendants knowingly disseminated false information or knew of undisclosed facts
- § 13A:12 Inferring scienter (recklessness) from “core operations”—The “core operations” doctrine
- § 13A:13 —“Plus factors” used in core operations, or in the totality analysis
- § 13A:14 Inferring scienter (recklessness) from departures / resignations / terminations of key personnel
- § 13A:15 Confidential witnesses
- § 13A:16 Corporate scienter/collective scienter

CHAPTER 13B. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER—SECOND CIRCUIT

- § 13B:1 Introduction and overview
- § 13B:2 —*Novak v. Kasaks*
- §§ 13B:3 to 13B:9 *[Reserved]*
- § 13B:10 Motive and opportunity—Generally
- § 13B:11 —Alleging that defendants benefitted in some concrete and personal way
- § 13B:12 —Generalized motives—Overview
- § 13B:13 — —Maintaining credit rating
- § 13B:14 — —Maintaining inflated stock price to increase compensation; Incentive compensation
- § 13B:15 — —Maintaining inflated stock price to ensure the company’s viability
- § 13B:16 — —Other generalized motives
- § 13B:17 —Inferring motive from insider stock transactions
- §§ 13B:18 to 13B:29 *[Reserved]*
- § 13B:30 Recklessness; Conscious misbehavior—Overview
- § 13B:31 —Inferring scienter from the defendants’ knowledge of/access to contradictory information—Overview
- § 13B:32 — —Specific reports
- § 13B:33 — —Content; context; timing
- § 13B:34 — —Red flags; Warnings; Public denials; Concealment
- § 13B:35 — —Core operations doctrine

- § 13B:36 —Inferring scienter from the defendants’ failure to review or check information that they had a duty to monitor, or their ignoring obvious signs of fraud
- § 13B:37 —Inferring scienter from defendant’ illegal conduct; Government investigations
- § 13B:38 —Inferring scienter from the sheer magnitude of the fraud; Sheer magnitude of misstatements; Temporal proximity of the corrective disclosure(s)
- § 13B:39 —Inferring scienter from executive departures, resignations, or terminations
- § 13B:40 —Inferring scienter from GAAP violations—
Overview
- § 13B:41 — —Opinions regarding the adequacy of loss reserves; Valuation allowances; Goodwill—*Fait* and *Omnicare*
- § 13B:42 — — —Other applications
- § 13B:43 —Inferring scienter from internal control deficiencies
- § 13B:44 —Inferring scienter when there is a “clear duty to disclose”
- § 13B:45 —Inferring scienter from Sarbanes-Oxley (SOX) certifications
- § 13B:46 —Inferring scienter from the defendant’s level of expertise or sophistication
- § 13B:47 —Inferring scienter from the defendant-company’s “tone at the top”
- § 13B:48 —Inferring scienter from the frequency, numerosity, and specificity of defendants’ statements.
- §§ 13B:49 to 13B:59 [*Reserved*]
- § 13B:60 Holistic scienter analysis
- § 13B:61 Pleading strong inference of scienter
- § 13B:62 Confidential witnesses; Confidential sources
- § 13B:63 Corporate scienter; Collective corporate scienter
- § 13B:64 Impermissible group pleading
- § 13B:65 Pleading “actual knowledge” under the safe harbor for forward-looking statements
- § 13B:66 Differing standards for pleading motive-based scienter versus pleading recklessness

CHAPTER 13C. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER—THIRD CIRCUIT

- § 13C:1 Introduction—Overview
- § 13C:2 —Motive and opportunity—Generally
- § 13C:3 —Recklessness—Generally

TABLE OF CONTENTS

- § 13C:4 —Pleading scienter after *Tellabs*
- §§ 13C:5 to 13C:9 *[Reserved]*
- § 13C:10 Inferring scienter (recklessness) from restated financial statements
- § 13C:11 Inferring scienter (recklessness) from internal control deficiencies; Mismanagement; “Tone at the top”
- § 13C:12 Inferring scienter (recklessness) from the departure of corporate executives
- § 13C:13 Inferring scienter (recklessness) from core operations
- § 13C:14 Inferring scienter (recklessness) from GAAP violations
- § 13C:15 Inferring scienter (recklessness) from the defendants’ knowledge of facts or access to information contradicting their public statements; Inferring scienter from the statements’ content and context; Inferring scienter from direct contradictions of the truth
- § 13C:16 Inferring scienter (recklessness) from government investigations
- § 13C:17 Inferring scienter (recklessness) from SOX certifications
- § 13C:18 Inferring scienter (motive) from executives’ insider trading of company stock
- § 13C:19 Inferring scienter (motive) from generalized motives
- §§ 13C:20 to 13C:39 *[Reserved]*
- § 13C:40 Confidential witnesses
- § 13C:41 Corporate scienter
- § 13C:42 Pleading scienter—*Tellabs*’ “reasonable person” test
- § 13C:43 “Actual knowledge” standard with forward-looking statements

CHAPTER 13D. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER—FOURTH CIRCUIT

- § 13D:1 Introduction—Overview
- § 13D:2 Holistic, comparative analysis
- § 13D:3 Recklessness—Overview
- § 13D:4 —Inferring scienter from executive position; Core operations doctrine
- § 13D:5 —Inferring knowledge from red flags
- § 13D:6 —Inferring scienter from GAAP violations
- § 13D:7 —Inferring scienter from the restatement of financials

PUBLICLY TRADED CORPORATIONS

- § 13D:8 —Inferring scienter from the “sheer magnitude” of the violation
- § 13D:9 —Inferring scienter from weak internal controls
- § 13D:10 —Inferring scienter from departures and resignations of key personnel
- § 13D:11 —Inferring scienter from the defendants’ reckless failure to disclose critical information; Recklessly misleading investors
- § 13D:12 —Scienter in the context of pharmaceutical drug trials
- § 13D:13 —Inferring scienter from the temporal proximity between the alleged misstatement and subsequent revelation of the truth
- §§ 13D:14 to 13D:29 *[Reserved]*
- § 13D:30 Motive and opportunity—Generally
- § 13D:31 Motive—Inferring scienter from generalized motives
- § 13D:32 —Inferring scienter from insider trading
- §§ 13D:33 to 13D:39 *[Reserved]*
- § 13D:40 Other—Auditor liability
- § 13D:41 —Group pleading doctrine
- § 13D:42 —Corporate scienter
- § 13D:43 —Confidential witnesses

**CHAPTER 13E. SECURITIES FRAUD
UNDER RULE 10B-5—SCIENTER—FIFTH
CIRCUIT**

- § 13E:1 Introduction—Overview
- § 13E:2 —Post-*Tellabs* framework
- §§ 13E:3 to 13E:19 *[Reserved]*
- § 13E:20 Inferring scienter (recklessness) from officer’s position within company; Core operations doctrine
- § 13E:21 Inferring scienter (recklessness) from access to information; Internal corporate reports
- § 13E:22 Inferring scienter (recklessness) from accounting restatements
- § 13E:23 Inferring scienter (recklessness) from GAAP violations
- § 13E:24 Inferring scienter (recklessness) from a lack of internal controls
- § 13E:25 Inferring scienter (recklessness) from the sheer magnitude of the misstatement or violation; The sheer magnitude of the fraud
- § 13E:26 Inferring scienter (recklessness) from repeated red flags or a sustained course of misconduct
- § 13E:27 Inferring scienter (recklessness) from an egregious

TABLE OF CONTENTS

	refusal to see the obvious; Egregious refusal to investigate the doubtful; Egregious misuse of industry-specific terminology
§ 13E:28	Inferring scienter (recklessness) from Sarbanes-Oxley (SOX) certifications
§ 13E:29	Inferring scienter (recklessness) from inappropriate tone at the top
§ 13E:30	Inferring scienter (recklessness) where the defendant's statements were subject to multiple (mixed) interpretations
§ 13E:31	Inferring scienter (recklessness) from the concealing of risks or trends relating to inventory, labor, etc.
§ 13E:32	Inferring scienter (recklessness) from officers' resignations / departures; Abrupt terminations
§§ 13E:33 to 13E:49	<i>[Reserved]</i>
§ 13E:50	Motive and opportunity—Generally
§ 13E:51	—Universal motives—Inferring scienter from generalized motives or goals
§ 13E:52	—“Crucial funds” exception
§ 13E:53	—Inferring scienter from insider trading; Insider stock sales
§ 13E:54	—Inferring scienter from an executive's desire to protect his/her job
§ 13E:55	—Inferring scienter from executive compensation
§§ 13E:56 to 13E:69	<i>[Reserved]</i>
§ 13E:70	Other—Confidential witnesses
§ 13E:71	—Corporate scienter; Group pleading rejected

CHAPTER 13F. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER—SIXTH CIRCUIT

§ 13F:1	Introduction—Overview
§ 13F:2	—Recklessness
§ 13F:3	Motive and opportunity
§ 13F:4	Corporate scienter
§ 13F:5	Post- <i>Tellabs</i> holistic three-step scienter analysis
§§ 13F:6 to 13F:19	<i>[Reserved]</i>
§ 13F:20	Inferring scienter— <i>Helwig</i> factors
§ 13F:21	— <i>Helwig</i> 's first factor—Insider trading at a suspicious time or in an unusual amount
§ 13F:22	— <i>Helwig</i> 's second factor—Divergence between internal reports and external statements on the same subject
§ 13F:23	— <i>Helwig</i> 's third factor—Temporal proximity
§ 13F:24	— <i>Helwig</i> 's fourth factor—Evidence of bribery or illegal conduct

- § 13F:25 — —*Helwig's* fifth factor—Existence of ancillary lawsuits
- § 13F:26 — —*Helwig's* sixth factor—Disregard of current factual information
- § 13F:27 — —*Helwig's* seventh factor—GAAP violations; Disclosure of accounting information in such a way that its negative implications could only be understood by someone with a high degree of sophistication
- § 13F:28 — —*Helwig's* eighth factor—Directors' personal interest in failing to inform disinterested directors of impending stock sales
- § 13F:29 — —*Helwig's* ninth factor—Defendants' motivation to save their jobs/salaries
- § 13F:30 Inferring scienter from concealment of risks; Covering-up problems
- § 13F:31 Inferring scienter from core operations; Access to information; Ability to monitor operations
- § 13F:32 Inferring scienter from red flags; Egregious refusal to see the obvious; Egregious failure to investigate
- § 13F:33 Inferring scienter from resignations or departures
- § 13F:34 Inferring scienter from government investigations
- § 13F:35 Inferring scienter from SOX certifications
- § 13F:36 Inferring scienter from the restatements of financial statements
- § 13F:37 Inferring scienter from the sheer magnitude of the fraud
- §§ 13F:38 to 13F:49 [*Reserved*]
- § 13F:50 Other—Confidential witnesses

CHAPTER 13G. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER—SEVENTH CIRCUIT

- § 13G:1 Introduction—Overview
- § 13G:2 Pleading strong inference of scienter—Overview
- § 13G:3 —*Tellabs*
- §§ 13G:4 to 13G:19 [*Reserved*]
- § 13G:20 Recklessness—Overview
- § 13G:21 Inferring scienter (recklessness) from GAAP violations
- § 13G:22 Inferring scienter (recklessness) from deficient internal controls
- § 13G:23 Inferring scienter (recklessness) from the sheer magnitude of the misrepresentations
- § 13G:24 Inferring scienter (recklessness) from the nature of the misrepresentations

TABLE OF CONTENTS

- § 13G:25 Inferring scienter (recklessness) from officers’ resignations/terminations
- § 13G:26 Inferring scienter (recklessness) from access to information
- § 13G:27 Inferring scienter (recklessness) from defendants’ positions
- § 13G:28 Inferring scienter (recklessness) from core operations; Core operations doctrine
- § 13G:29 Inferring scienter (recklessness) from red flags
- § 13G:30 Inferring scienter (recklessness) where the defendants made the challenged statements while in possession of non-public contradictory information
- § 13G:31 Inferring scienter (recklessness) from the concealment or covering-up of misdeeds
- §§ 13G:32 to 13G:50 *[Reserved]*
- § 13G:51 Motive and opportunity—Generally
- § 13G:52 —Inferring scienter (motive) from insider stock sales
- § 13G:53 —Inferring scienter (motive) from universal motives; Generalized motives
- §§ 13G:54 to 13G:70 *[Reserved]*
- § 13G:71 Other—Confidential sources; Confidential witnesses
- § 13G:72 —Actual knowledge for forward-looking statements
- § 13G:73 —Group pleading

CHAPTER 13H. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER—EIGHTH CIRCUIT

- § 13H:1 Overview—Introduction and background
- § 13H:2 —Recklessness
- § 13H:3 —Motive and opportunity
- §§ 13H:4 to 13H:9 *[Reserved]*
- § 13H:10 Pleading scienter—Pleading scienter under Rule 9(b) and the PSLRA
- § 13H:11 —Post-*Tellabs* scienter framework
- § 13H:12 —Vague, conclusory allegations are insufficient
- § 13H:13 —Pleading fraud by hindsight is impermissible
- § 13H:14 Pleading “corporate mismanagement” is not actionable
- §§ 13H:15 to 13H:19 *[Reserved]*
- § 13H:20 Proving scienter with direct and circumstantial evidence
- § 13H:21 Inferring scienter from the defendants’ engaging in deliberately illegal behavior

- § 13H:22 Inferring scienter from the defendants' knowledge of falsity—Overview
- § 13H:23 —Examples of where defendants made materially inaccurate statements while in possession of contradictory facts
- § 13H:24 —Examples of court decisions finding no strong inference of scienter amid plaintiffs' claims of contemporaneous falsity
- § 13H:25 —The “core operations” doctrine
- §§ 13H:26 to 13H:27 [*Reserved*]
- § 13H:28 Inferring scienter from the defendants' ignoring “red flags” or failing to check information they had a duty to monitor
- § 13H:29 Inferring scienter from GAAP violations—Overview
- § 13H:30 —Pleading with particularity—*K-tel*
- § 13H:31 —Pleading improper revenue recognition with particularity
- § 13H:32 —GAAP violations combined with other indicia of scienter
- § 13H:33 Inferring scienter from channel stuffing
- § 13H:34 Inferring scienter (recklessness) based on obviousness or the “sheer magnitude” of the fraud
- § 13H:35 Inferring scienter from “sheer magnitude” combined with motive
- § 13H:36 Inferring scienter (recklessness) from GAAP violations of large magnitude/scope
- § 13H:37 Inferring scienter from temporal proximity
- § 13H:38 Inferring scienter (recklessness) based on SOX certifications
- § 13H:39 Inferring scienter (recklessness) from failure to write-down/write-off assets
- § 13H:40 Inferring scienter from resignations or departures of key personnel
- § 13H:41 Inferring scienter (motive) from generalized motive allegations
- § 13H:42 Inferring scienter (motive) from incentive bonuses and compensation packages—Overview
- § 13H:43 —Cases finding scienter—*Green Tree*
- § 13H:44 — —*In re Digi Int'l*
- § 13H:45 —Cases finding no scienter—*Kushner v. Beverly Enterprises*
- § 13H:46 — —Other cases
- § 13H:47 Inferring scienter (motive) from insider trading—Overview
- § 13H:48 —Cases finding insider trading as probative of scienter

TABLE OF CONTENTS

- § 13H:49 —Cases finding insider trading as non-indicative of scienter
- § 13H:50 —Plaintiff must show context
- § 13H:51 —Timing, amount, and “clustering”
- § 13H:52 —Amount and percentage of total holdings sold; net stock sales
- § 13H:53 —Trading windows
- § 13H:54 —Absence of insider sales as negating an inference of scienter
- § 13H:55 Inferring scienter (motive) from the desire to consummate transactions or negotiate better terms
- § 13H:56 Inferring scienter (motive) from the desire to raise capital, improve cash-flow, or fuel acquisitions
- § 13H:57 Inferring scienter from a holistic analysis of collective indicia—Overview
- § 13H:58 —Cases finding scienter
- § 13H:59 —Cases finding no scienter
- § 13H:60 Group pleading doctrine / group-published doctrine
- § 13H:61 Confidential sources; Confidential witnesses
- § 13H:62 Corporate scienter

CHAPTER 13I. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER—NINTH CIRCUIT

- § 13I:1 Overview
- § 13I:2 “Motive and opportunity” rejected as stand-alone standard
- § 13I:3 “Deliberate or conscious recklessness” standard
- §§ 13I:4 to 13I:19 *[Reserved]*
- § 13I:20 Inferring scienter from the defendants’ knowledge of falsity—Introduction and overview
- § 13I:21 —Contemporaneous contradictory statements or reports
- § 13I:22 —Confidential witnesses
- § 13I:23 —Where falsity and scienter are inferred from the same set of facts; Where falsity is “readily apparent” to management; Where the statements themselves indicate contemporaneous contradictions
- § 13I:24 —Evidence showing that the defendants appreciated the gravity of the risk of misleading others
- § 13I:25 —Defendants’ personal involvement in the subject matter of the misstatements
- § 13I:26 —Defendants’ “shifting explanations” as probative of scienter

PUBLICLY TRADED CORPORATIONS

- § 13I:27 —Other forms of contemporaneous knowledge of falsity; Evidence that contradicts defendant’s claim that they were unaware of issue
- § 13I:28 —Context and content of a misrepresentation
- § 13I:29 —“Deliberate recklessness”; “Reckless omissions”
- § 13I:30 —That the defendants “should have known” of the fraud is insufficient
- §§ 13I:31 to 13I:49 *[Reserved]*
- § 13I:50 “Core operations doctrine”—Overview
- § 13I:51 —Inferring scienter from knowledge of the company’s core operations
- § 13I:52 —Inferring scienter from officers’ direct involvement in the production of false accounting statements
- § 13I:53 —Inferring scienter where the complaint includes specific and detailed statement about defendants’ actual knowledge
- § 13I:54 —Inferring scienter where the officers made detailed factual statements that contradicting important data to which they had access
- § 13I:55 —Inferring scienter where defendants made repeated representations to the investing public that they were knowledgeable and informed
- § 13I:56 —Inferring scienter where it would be “absurd to suggest” that top management was unaware of the problem or issue—Examples of cases finding a strong inference of scienter
- § 13I:57 —Inferring scienter where it would be “absurd to suggest” that top management was unaware of the problem or issue—Examples of cases finding no strong inference of scienter
- § 13I:58 —Inferring scienter in the context of small companies with hands-on management
- § 13I:59 —Other
- §§ 13I:60 to 13I:79 *[Reserved]*
- § 13I:80 Inferring scienter from the magnitude or obviousness of the violation
- § 13I:81 Inferring scienter from efforts to conceal, hide, or cover up the truth
- § 13I:82 Inferring scienter from GAAP violations
- § 13I:83 Inferring scienter from the restatement of financial statements
- § 13I:84 Inferring scienter from inadequate internal controls
- § 13I:85 Inferring scienter from “channel stuffing” or “pipeline stuffing”
- § 13I:86 Inferring scienter from officers’ departures, resignations, or terminations

TABLE OF CONTENTS

- § 13I:87 Inferring scienter from false Sarbanes-Oxley (“SOX”) certifications
- § 13I:88 Inferring scienter (motive) from stock sales or insider trading of stock
- § 13I:89 Inferring scienter (motive) from stock options, cash bonuses, or compensation structures
- § 13I:90 Inferring scienter (motive) from corporate acquisitions/mergers
- § 13I:91 Inferring scienter (motive) from desire to obtain credit, secure financing, raise capital, or boost the company’s profitability and stock prices
- § 13I:92 Inferring scienter from company-wide pressure campaigns
- § 13I:93 Inferring scienter from senior executives’ desire to comply with external and internal pressures and mandates
- § 13I:94 Inferring scienter from close temporal proximity between false statements and the subsequent disclosure of the truth
- § 13I:95 Inferring scienter from criminal, regulatory, or governmental investigations.
- § 13I:96 Other indicia of scienter
- §§ 13I:97 to 13I:113 *[Reserved]*
- § 13I:114 Totality of circumstances; Holistic analysis
- § 13I:115 Summary of post-*Tellabs* scienter framework
- § 13I:116 Corporate scienter

CHAPTER 13J. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER—TENTH CIRCUIT

- § 13J:1 Overview—Introduction and background
- § 13J:2 —Recklessness
- § 13J:3 —Motive and opportunity
- § 13J:4 —Pre-*Tellabs* “strong inference” test and a comparative evaluation of scienter
- §§ 13J:5 to 13J:9 *[Reserved]*
- § 13J:10 Pleading scienter post-*Tellabs*—“Strong inference” test
- § 13J:11 —Certainty of inference
- § 13J:12 —Post-*Tellabs* scienter framework
- § 13J:13 —Viewing the totality of allegations as a whole
- § 13J:14 —Pleading scienter under the PSLRA
- § 13J:15 —Pleading under Rule 9(b)
- § 13J:16 —Vague or conclusory allegations will not suffice
- § 13J:17 —Fraud by hindsight is impermissible

- §§ 13J:18 to 13J:29 *[Reserved]*
- § 13J:30 Reckless non-disclosure of material facts
- § 13J:31 Inferring scienter—Overview
- § 13J:32 Inferring scienter from an executive’s position within the company; Core operations doctrine
- § 13J:33 Inferring scienter from a combination of position; access to information; divergence of internal reports from external reports; and other factors
- § 13J:34 Inferring scienter (recklessness) from the sheer magnitude of fraud
- § 13J:35 Inferring scienter from pervasive “red flags”
- § 13J:36 Inferring scienter from ineffective internal controls
- § 13J:37 Inferring scienter from GAAP violations—Overview
- § 13J:38 —*Adams v. Kinder-Morgan, Inc.*
- § 13J:39 —Sham transactions
- § 13J:40 —Simplicity of GAAP violation
- § 13J:41 Inferring scienter from GAAP violations combined with other indicia of scienter—Overview
- § 13J:42 Inferring scienter from GAAP violations combined with violations of internal policies
- § 13J:43 Inferring scienter from GAAP violations combined with magnitude/ pervasiveness
- § 13J:44 Inferring scienter from GAAP violations combined with restatement of financial statements
- § 13J:45 Inferring scienter from GAAP violations relating to revenue manipulations
- § 13J:46 Inferring scienter from GAAP violations relating to provisions for doubtful accounts
- § 13J:47 Inferring scienter from GAAP violations relating to the improper recording of assets
- § 13J:48 Inferring scienter or recklessness—Other
- § 13J:49 Inferring scienter from “motive and opportunity”
- § 13J:50 Inferring scienter (motive) from insider trading allegations
- § 13J:51 Inferring scienter (motive and opportunity) from the acquisition of shares at unfairly low value
- § 13J:52 Inferring scienter (motive and opportunity) from bonus compensation tied to misstatement
- § 13J:53 Inferring scienter from generalized motives—Desire to maintain credit or bond rating
- § 13J:54 —Desire to raise capital or consummate company transactions
- § 13J:55 —Desire to protect positions within the company
- § 13J:56 —Desire to further company interests and/or to appear successful
- § 13J:57 Factors weighing against the inference of scienter

TABLE OF CONTENTS

- § 13J:58 Defendant’s subjective beliefs cannot negate recklessness.
- §§ 13J:59 to 13J:68 [*Reserved*]
- § 13J:69 Corporate scienter
- § 13J:70 Confidential witnesses
- § 13J:71 Actual knowledge under the PSLRA safe harbor for forward-looking statements
- § 13J:72 Post-*Tellabs* amendments of a deficient complaint
- § 13J:73 Group pleading doctrine—Overview
- § 13J:74 —*Celestial Seasonings* and its progeny
- § 13J:75 —*In re Williams Securities Litigation*
- § 13J:76 —*Qwest* (2004)
- § 13J:77 —*Crocker v. Carrier Access Corp.*

Volume 4

CHAPTER 13K. SECURITIES FRAUD UNDER RULE 10B-5—SCIENTER IN THE ELEVENTH CIRCUIT

- § 13K:1 Introduction and background
- § 13K:2 Rule 9(b) and PSLRA pleading
- § 13K:3 Recklessness
- § 13K:4 Motive and opportunity
- § 13K:5 Pleading scienter—Strong inference of scienter
- § 13K:6 —Group pleading doctrine
- § 13K:7 —Confidential witnesses and anonymous sources
- § 13K:8 Generalized or conclusory allegations of knowledge and recklessness
- § 13K:9 Direct evidence of scienter
- § 13K:10 Inferring scienter—Overview
- § 13K:11 —Admissions by defendant
- § 13K:12 Imputing knowledge to defendants—Overview
- § 13K:13 —Access to reports and internal data
- § 13K:14 —“Core operations doctrine”
- § 13K:15 —Defendants’ high level management positions
- § 13K:16 Imputing knowledge to outside directors or non-key personnel
- § 13K:17 Inferring scienter (recklessness) from GAAP violations—Overview
- § 13K:18 Inferring scienter from GAAP violations—Factors to consider
- § 13K:19 Inferring scienter (recklessness) from the sheer magnitude of fraud

- § 13K:20 Inferring scienter (motive) from suspicious or unusual stock trading
- § 13K:21 Inferring scienter (motive) from particularized allegations of profits by virtue of dealing through related companies or exercising stock options
- § 13K:22 Inferring scienter (motive) from compensation/ bonuses tied to financial or stock performance
- § 13K:23 Inferring scienter (motive) from aggressive growth strategy
- § 13K:24 Inferring scienter (recklessness) from false Sarbanes-Oxley (SOX) certifications
- § 13K:25 Inferring scienter (recklessness) by ignoring red flags, warnings, or alarms
- § 13K:26 Inferring scienter (recklessness) from false rationales for restating financials
- § 13K:27 Inferring scienter (recklessness) from restatements, auditor resignations, departures, shake-ups, or government investigations
- § 13K:28 Inferring scienter (recklessness) from evidence that defendants were confronted directly with improprieties; Widespread publicity of improprieties
- § 13K:29 Inferring scienter (recklessness) based on allegations of company-wide misconduct
- § 13K:30 Inferring scienter (recklessness) from significant price decline following the disclosures at issue
- § 13K:31 Inferring scienter from the content, context, timing, or temporal proximity of the implicated statements
- § 13K:32 Inferring (or negating) scienter—Other
- § 13K:33 Totality of facts—Aggregating facts to infer scienter
- § 13K:34 Corporate scienter/Collective scienter

CHAPTER 14. SECURITIES FRAUD UNDER RULE 10B-5—RELIANCE

- § 14:1 Overview of the reliance element—Introduction and background
- § 14:2 —Transaction causation
- § 14:3 —*Stoneridge*
- § 14:4 —Relation between reliance, economic loss, and loss causation
- § 14:5 Reliance and event studies
- §§ 14:6 to 14:9 *[Reserved]*
- § 14:10 Presumed reliance—Overview
- § 14:11 —*Affiliated Ute* presumption of reliance—Overview
- § 14:12 — —Misrepresentations vs. omissions

TABLE OF CONTENTS

§ 14:13 — — — *Affiliated Ute* in mixed cases—Definition of “mixed cases”

§ 14:14 — — — Test for mixed cases in the First Circuit

§ 14:15 — — — Test for mixed cases in the Second Circuit

§ 14:16 — — — Test for mixed cases in the Third Circuit

§ 14:17 — — — Test for mixed cases in the Fourth Circuit

§ 14:18 — — — Test for mixed cases in the Fifth Circuit

§ 14:19 — — — Test for mixed cases in the Sixth Circuit

§ 14:20 — — — Test for mixed cases in the Seventh Circuit

§ 14:21 — — — Test for mixed cases in the Eighth Circuit

§ 14:22 — — — Test for mixed cases in the Ninth Circuit

§ 14:23 — — — Test for mixed cases in the Tenth Circuit

§ 14:24 — — — Test for mixed cases in the Eleventh Circuit

§ 14:25 — — — Test for mixed cases in the D.C. Circuit

§ 14:26 — — — Scheme liability claims premised on omissions; Concealment of deceptive conduct for scheme liability claims

§§ 14:27 to 14:39 [Reserved]

§ 14:40 Presumed reliance—Fraud-on-the-market—Overview

§ 14:41 — — — Invoking the *Basic* fraud-on-the-market presumption

§ 14:42 — — — Rebutting the *Basic* fraud-on-the-market presumption

§ 14:43 — — — *Amgen Inc. v. Connecticut Retirement Plans and Trust Funds*

§ 14:44 — — — “Price impact” and *Halliburton Co. v. Erica P. John Fund*

§ 14:45 — — — Applying the *Basic* presumption in class actions; Assessing generic misrepresentations at class certification

§ 14:46 — — — Market efficiency—*Cammer/Krogman* factors—Overview

§ 14:47 — — — First *Cammer* factor

§ 14:48 — — — Second *Cammer* factor

§ 14:49 — — — Third *Cammer* factor

§ 14:50 — — — Fourth *Cammer* factor

§ 14:51 — — — Fifth *Cammer* factor

§ 14:52 — — — Weighing the *Cammer* factors

§ 14:53 — — — *Krogman* factors

§ 14:54 — — — Other factors

§ 14:55 — — — Third Circuit—*Semerenko; Zlotnick*

§§ 14:56 to 14:59 [Reserved]

§ 14:60 Reasonableness of reliance

§ 14:61 — — — Plaintiff’s lack of due diligence

§ 14:62 — — — Sophistication of plaintiff/complexity of transaction

- § 14:63 —Integration and non-reliance clauses; Disclaimers
- § 14:64 Eighth Circuit—Reliance—Overview
- § 14:65 —Justifiable reliance
- § 14:66 —Presuming reliance in omission cases (*Affiliated Ute*)
- § 14:67 —Presuming reliance based on “fraud-on-the-market”
- § 14:68 —Reliance—Efficient market test using the “*Cammer* factors”
- § 14:69 — —Timing of the alleged fraud
- § 14:70 —Reasonableness of reliance and due care
- § 14:71 Fraud created the market
- § 14:72 Truth on the Market Defense
- § 14:73 Transaction causation in the context of freeze-out mergers

CHAPTER 15. SECURITIES FRAUD UNDER RULE 10B-5—LOSS CAUSATION

- § 15:1 Loss causation—Introduction
- § 15:2 —PSLRA
- § 15:3 Policy behind loss causation requirement
- § 15:4 “Transaction causation” distinguished
- § 15:5 *Dura Pharmaceuticals* and *Lentell*
- § 15:6 —Rejecting the “price inflation” approach
- § 15:7 —Adopting the “price correction” approach
- § 15:8 —Linking the loss to the alleged misrepresentation
- § 15:9 —“Fraud-on-the-market” theory of loss causation
- § 15:10 —Unresolved issues: requirement of a sale of shares (“sell-to-sue” requirement); subsequent price recovery
- § 15:11 —Unresolved issues: in-and-out stock traders
- § 15:12 Overview to corrective disclosures, revelation of the truth, and confirmatory information
- § 15:13 Corrective disclosures—Generally
- § 15:14 —Confirmatory information
- § 15:15 Pleading loss causation; Rule 8 vs. Rule 9(b) pleading standard
- § 15:16 Limitations on *Dura Pharms.*—Construing *Dura* narrowly
- § 15:17 Limitations on *Dura*—Does *Dura Pharms.* merely provide a “negative prescription”?
- § 15:18 Limitations on *Dura Pharms.*—*Dura Pharms.* applies only to loss causation, not to transaction causation
- § 15:19 —Non-applicability to § 11 claims
- § 15:20 Post-*Dura Pharms* corrective disclosures
- § 15:21 *Lentell*’s “Materialization of risk” approach

TABLE OF CONTENTS

- § 15:22 Loss causation and “intervening events”
- § 15:23 First Circuit—Post-*Dura Pharms.* framework
- § 15:24 —Applying *Lentell*
- § 15:25 —Concealed or misstated risks—Analysts
- § 15:26 —Survey of district court opinions
- § 15:27 Second Circuit—Overview
- § 15:28 —Pleading and proving loss causation
- § 15:29 —*Lentell* and its progeny
- § 15:30 —Materialization of the risk analysis and the “public disclosure” test
- § 15:31 —Loss causation in securities context viz. proximate cause in common law fraud context
- § 15:32 Third Circuit—Pre-*Dura Pharms.* legal standard largely unchanged
 - § 15:33 —Overview of post-*Dura Pharms.* standard
- § 15:34 Third Circuit and Second Circuit compared
- § 15:35 Third Circuit—Typical vs. non-typical
- §§ 15:36 to 15:37 [*Reserved*]
- § 15:38 Third Circuit—“Substantial factor” standard and intervening causes
 - § 15:39 —Corrective disclosures; Revelation of the “truth”
- §§ 15:40 to 15:41 [*Reserved*]
- § 15:42 Third Circuit—Loss causation and transaction causation cannot be merged
 - § 15:43 —Inflated purchase price
 - § 15:44 —*Intelligroup*
 - § 15:45 — —Linkage of specific disclosure to loss
 - § 15:46 —No sale of shares requirement
- § 15:47 Fourth Circuit—Pleading loss causation with sufficient specificity; Corrective disclosures and the “amalgam” approach
 - § 15:48 —Inflated purchase price theory
- § 15:49 [*Reserved*]
- § 15:50 Fifth Circuit—Overview
- § 15:51 —Loss causation; corrective disclosures; fraud-on-the-market
- § 15:52 [*Reserved*]
- § 15:53 Fifth Circuit—Loss causation and class certification
 - § 15:54 —Materialization of risk
- § 15:55 Sixth Circuit—Overview and summary
 - § 15:56 —Other issues
- § 15:57 Seventh Circuit—Overview and summary
 - § 15:58 —*Ray v. Citigroup*
 - § 15:59 —Consistency with *Dura*
- § 15:60 —The “typical” fraud-on-the-market case

- § 15:61 —Materialization of risk approach
- § 15:62 Eighth Circuit—Overview
- § 15:63 —“Corrective disclosures”
- § 15:64 —Cases not involving fraud-on-the-market
- § 15:65 —Post-*Dura* examples of sufficient pleading of loss causation
- § 15:66 —Post-*Dura* examples of insufficient pleading of loss causation
- § 15:67 Ninth Circuit—Overview
- § 15:68 —Corrective disclosures
- § 15:69 —Post-*Dura Pharms*
- § 15:70 —*Daou Systems*
- § 15:71 —Survey of post-*Dura* case law
- § 15:72 —“Substantial factor” vs. “sole factor”
- § 15:73 —Private sales of a privately traded company
- § 15:74 —Pleading loss causation
- § 15:75 —Derivative 10(b) actions
- § 15:76 —Isolating economic losses
- § 15:77 Tenth Circuit—Summary and overview
- § 15:78 —Corrective disclosures; materialization of risk
- § 15:79 Eleventh Circuit—Overview

CHAPTER 16. SECURITIES FRAUD UNDER RULE 10B-5—CONTROL PERSON LIABILITY; AIDING AND ABETTING LIABILITY; STATUTE OF LIMITATIONS FOR RULE 10B-5 ACTIONS

- § 16:1 Control person liability—Introduction and overview—Generally
- § 16:2 — —Congressional purpose of § 20(a)
- § 16:3 — —Alleging a primary violation
- § 16:4 — —Control element—Burden of proof
- § 16:5 — —Definition of control
- § 16:6 — —Tests for evaluating control
- § 16:7 — —Fact intensive inquiry into “control”
- § 16:8 — —Pleading requirements
- §§ 16:9 to 16:19 [*Reserved*]
- § 16:20 Control person liability—First Circuit—*Prima facie* case
- § 16:21 — —Culpable participation
- §§ 16:22 to 16:29 [*Reserved*]
- § 16:30 Control person liability—Second Circuit—*Prima facie* case
- § 16:31 — —Control; Culpable participation

TABLE OF CONTENTS

§ 16:32 — —Pleading standard

§§ 16:33 to 16:39 [*Reserved*]

§ 16:40 Control person liability—Third Circuit—*Prima facie* case

§ 16:41 — —Control

§ 16:42 — — —Examples of sufficiently pleading control

§ 16:43 — —Culpable participation

§§ 16:44 to 16:49 [*Reserved*]

§ 16:50 Control person liability—Fourth Circuit—*Prima facie* case; Pleading requirements

§ 16:51 — —Control requirement

§ 16:52 — —Fifth Circuit—*Prima facie* case; Pleading

§ 16:53 — —Control

§ 16:54 — —Sixth Circuit—*Prima facie* case; Pleading

§ 16:55 — —Control

§ 16:56 — —Seventh Circuit—*Prima facie* case; Pleading

§ 16:57 — —Control

§§ 16:58 to 16:69 [*Reserved*]

§ 16:70 Control person liability—Eighth Circuit—*Prima facie* case

§ 16:71 — —Rejecting culpable participation

§ 16:72 — —Ninth Circuit—*Prima facie* case

§ 16:73 — —Control

§ 16:74 — —Pleading standard

§ 16:75 — —Tenth Circuit

§ 16:76 — —Eleventh Circuit—*Prima facie* case

§ 16:77 — —Control

§ 16:78 — —Defenses—Section 15

§ 16:79 — —Section 20(a)

§ 16:80 Respondeat superior liability

§§ 16:81 to 16:99 [*Reserved*]

§ 16:100 Aiding and abetting liability—*Central Bank*

§ 16:101 — —Line between primary and secondary liability

§ 16:102 Effect of *Central Bank* on conspiracy claims

§ 16:103 Identifying “makers” of statements—Impact of *Central Bank* and *Janus Capital Group*

§ 16:104 — —Impact of *Janus*

§§ 16:105 to 16:119 [*Reserved*]

§ 16:120 Statute of limitations—Overview

§ 16:121 — —Discovery of the facts constituting a securities fraud violation—“Discovery” of fraud: *Merck*

§ 16:122 — —Applying *Merck’s* “discovery” standard

§ 16:123 — —Inquiry notice

§ 16:124 — —Third Circuit—Overview

§ 16:125 — —*Pharmacia* and *Merck*

- § 16:126 —Equitable tolling and the 5-year statute of repose
- § 16:127 —SEC enforcement actions

PART V. REGULATION OF SECURITIES TRANSACTIONS AMONG OFFICERS, DIRECTORS, AND SHAREHOLDERS

CHAPTER 17. REGULATION OF SECURITIES TRANSACTIONS OF CORPORATE INSIDERS

I. HISTORICAL OVERVIEW

- § 17:1 Introduction
- § 17:2 Insider trading
- § 17:3 Common-law regulation of insider trading

II. INSIDER TRADING LIABILITY UNDER RULE 10B-5

- § 17:4 Introduction to insider trading liability under Rule 10b-5
- § 17:5 The equal access (possession) theory
- § 17:6 Classical theory and misappropriation theory—
Overview
- § 17:7 Classical theory
- § 17:8 Misappropriation theory
- § 17:9 Evolution of the misappropriation theory—Circuit
split
- § 17:10 —*U.S. v. O'Hagan*
- § 17:11 Possession vs. use—Introduction and overview
- § 17:12 —*SEC v. Adler*
- § 17:13 —*US v. Smith*

A. REGULATION FD: SELECTIVE DISCLOSURE

- § 17:14 Regulation FD and Rules 10b5-1 and 10b5-2
- § 17:15 Regulation FD—Rule 100
- § 17:16 —Intentional and nonintentional selective
disclosures: timing of required public disclosures
- § 17:17 —Other matters
- § 17:18 Section 20A of the Exchange Act
- § 17:19 [*Reserved*]

TABLE OF CONTENTS

§ 17:20 Regulation FD—SEC interpretations

B. INSIDER TRADING RULES

§ 17:21 Rule 10b5-1—Introduction and overview

§ 17:22 —Provisions of Rule 10b5-1

§ 17:23 Rule 10b5-2

III. EXTENSION OF RULE 10B-5 INSIDER TRADING LIABILITY

§ 17:24 Insiders and temporary insiders

§ 17:25 Establishing tipper/tippee liability

§ 17:26 Scope of tipper/tippee liability under Rule 10b-5

§ 17:27 Aiding and abetting liability

IV. DEFENSES, REMEDIES AND ENFORCEMENT

§ 17:28 Defenses

§ 17:29 Remedies under Rule 10b-5

§ 17:30 —Damages

§ 17:31 —Equitable relief

§ 17:32 Criminal prosecution of insider traders

V. ADDITIONAL SOURCES OF INSIDER TRADING LIABILITY

§ 17:33 Insider trading during tender offers and SEC Rule 14e-3

§ 17:34 U.S. Supreme Court's *O'Hagan* decision and § 14(e) of Exchange Act and SEC Rule 14e-3(a)

§ 17:35 Regulation of short-swing transactions under Section 16

§ 17:36 Section 16(a)

§ 17:37 —Definition of officer

§ 17:38 —Definition of beneficial owner

§ 17:39 —Options and other derivative securities

§ 17:40 Section 16(b)—Short-swing transactions

§ 17:41 Insider trading and the Racketeer Influenced Corrupt Organizations Act

§ 17:42 Insider Trading Sanctions Act of 1984

§ 17:43 Insider Trading and Securities Fraud Enforcement Act of 1988

§ 17:44 Security Enforcement Remedies and Penny Stock Reform Act of 1990

§ 17:45 —Cease and Desist Authority

§ 17:46 —Civil Penalties

- § 17:47 —Dodd-Frank Act Amendments
- § 17:48 Market Reform Act of 1990
- § 17:49 Securities Act Amendments of 1990
- § 17:50 The PSLRA, Regulation FD, and the Sarbanes-Oxley Act of 2002
- § 17:51 Regulation BTR: Insider Trading During Pension Fund Blackout Periods

PART VI. ANTITAKEOVER LEGISLATION

CHAPTER 18. ANTITAKEOVER LEGISLATION

- § 18:1 Overview
- § 18:2 Business combination statutes
- § 18:3 Control share acquisition statutes
- § 18:4 Fair price statutes
- § 18:5 Disclosure statutes
- § 18:6 Directors' duties statutes/multiconstituency statutes
- § 18:7 Shareholder rights plan endorsement statutes
- § 18:8 Other statutes with antitakeover effects—
Antigreenmail statutes
- § 18:9 —“Cashout” statutes
- § 18:10 —Staggered board/classified board statutes
- § 18:11 Additional statutory developments

Table of Laws and Rules

Table of Cases

Index